Who is sponsoring NCT05923151?

NCT05923151 is sponsored by Jie Wang.

What drugs are being tested in NCT05923151?

Interventions in NCT05923151: The cranial-caudal mixed medial approach.

What condition does NCT05923151 study?

NCT05923151 studies Intraoperative Blood Loss, Postoperative Complications, Pathology.

Is NCT05923151 still recruiting?

NCT05923151 is currently completed. Last updated 28 June 2023.

Last reviewed 2023-06-28 · How we verify

NCT05923151

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Cranial-caudal Mixed Medial Approach for Laparoscopic Right Hemicolectomy

Completed NA Last updated 28 June 2023

What this trial tests

NA trial testing The cranial-caudal mixed medial approach in Intraoperative Blood Loss in 148 participants. Completed in 1 February 2023.

Timeline

1 February 2017

Primary endpoint
30 June 2022

1 February 2023

Quick facts

Lead sponsor	Jie Wang
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	148
Start date	1 February 2017
Primary completion	30 June 2022
Estimated completion	1 February 2023
Sites	1 location across China

Drugs / interventions tested

The cranial-caudal mixed medial approach

Conditions studied

Intraoperative Blood Loss — all drugs for Intraoperative Blood Loss →
Postoperative Complications — all drugs for Postoperative Complications →
Pathology — all drugs for Pathology →

Sponsor

Jie Wang — full company profile →

Who can join

Adults 18 to 70, any sex, with Intraoperative Blood Loss or Postoperative Complications. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To explore the feasibility and effectiveness of the cranial-caudal mixed medial approach in laparoscopic right hemicolectomy with complete mesocolic excision. Laparoscopic right hemicolectomy using the cranial-caudal mixed medial approach is safe and feasible, can shorten the operation time, reduce the risk of intraoperative bleeding, and has good clinical results.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Intraoperative Blood Loss

Currently open trials in the same condition.

NCT06399445 — Measurement of Blood Loss in Adenotonsillectomy During General Anesthesia According to the Application of Nondepolarizin · Phase 4 · recruiting

Other Jie Wang trials

Trials by the same sponsor.

NCT03083119 — Efficacy and Safety of Xuesaitong Soft Capsule for Coronary Heart Disease Unstable Angina · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05923151 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jie Wang
Last refreshed: 28 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05923151.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing